TriangleElranatamab (NCT06138275)
Elranatamab trial for Refractory Multiple Myeloma (NCT06138275). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed, refractory multiple myeloma who responded at least partly to idecabtagene vicleucel after at least four prior treatment lines.
The idea: elranatamab links T cells to myeloma cells to direct immune attack. Given injections under the skin for six cycles, it is tested as consolidation after CAR T treatment. Dosing becomes less frequent after two cycles. Researchers measure complete responses and progression-free survival. Prior BCMA bispecifics are excluded.
This phase 2 study plans 32 patients. Noopur Raje leads at Massachusetts General Hospital; three Boston sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.